Dorsey Wright & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Dorsey Wright & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,504	Closed	-$1.59M	–	359
2022 Q4	$1.59M	Buy	+5,504	New	+$1.68M	0.46%	95
2022 Q2	$1.66M	Buy	+5,902	New	+$1.58M	0.49%	91
2020 Q4	–	Sell	-12,354	Closed	-$3.36M	–	391
2020 Q3	$3.36M	Sell	12,354 -868	-7%	-$239K	0.61%	46
2020 Q2	$3.84M	Sell	13,222 -586	-4%	-$159K	0.78%	30
2020 Q1	$3.29M	Buy	+13,808	New	+$3.17M	1.25%	28
2019 Q2	–	Sell	-16,505	Closed	-$3.04M	–	342
2019 Q1	$3.04M	Buy	+16,505	New	+$3.05M	0.73%	70
2018 Q4	–	Sell	-17,087	Closed	-$3.29M	–	353
2018 Q3	$3.29M	Buy	17,087 +577	+3%	+$103K	0.6%	73
2018 Q2	$2.81M	Buy	16,510 +1,382	+9%	+$214K	0.41%	74
2018 Q1	$2.47M	Buy	15,128 +349	+2%	+$57K	0.38%	75
2017 Q4	$2.21M	Sell	14,779 -8,651	-37%	-$1.28M	0.4%	82
2017 Q3	$3.56M	Buy	23,430 +10,830	+86%	+$1.63M	0.82%	61
2017 Q2	$1.62M	Buy	+12,600	New	+$1.52M	0.5%	96

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dorsey Wright & Associates's VRTX Position: Q1 2023 in Review

Dorsey Wright & Associates sold out of Vertex Pharmaceuticals (VRTX) in Q1 2023, closing a stake of 5,504 shares — an estimated $1.59M sold.

Dorsey Wright & Associates first reported a position in VRTX in Q2 2017 and held it in 12 quarters. The position peaked at $3.84M in Q2 2020. 1,207 funds tracked by Wall St. Rank hold VRTX as of Q1 2023.

Dorsey Wright & Associates reported no remaining Vertex Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Dorsey Wright & Associates sold 5,504 Vertex Pharmaceuticals shares in Q1 2023, an estimated $1.59M.
Dorsey Wright & Associates first reported a position in Vertex Pharmaceuticals in Q2 2017 and held it in 12 quarters.
Dorsey Wright & Associates's Vertex Pharmaceuticals position peaked at $3.84M in Q2 2020.
1,207 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2023.

Based on Dorsey Wright & Associates's 13F filing for Q1 2023, filed 20 Apr 2023.